RecruitingEarly Phase 1NCT06584786

Therapeutic Effects of Jing Si Herbal Tea for COPD

Therapeutic Effects of Jing Si Herbal Tea for Chronic Obstructive Pulmonary Disease: A Comprehensive Investigation From Clinical to Basic Research


Sponsor

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Enrollment

120 participants

Start Date

Jan 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Chronic obstructive pulmonary disease (COPD), a leading cause of global mortality, significantly impairs health-related quality of life (HRQL). COPD is characterized by airway inflammation and lung tissue damage. Jing Si herbal tea (JSHT) is known to have anti-inflammatory effects but has not been explored for treating COPD. This study investigated the potential of JSHT as an adjuvant therapy for COPD. This randomized controlled study focused on patients with COPD in the exacerbation and stable phases. The control group received the standard treatment, and the JSHT group received the standard treatment plus JSHT. Both groups underwent HRQL assessments, blood tests, and cellular studies involving five different groups to assess the effect of JSHT on damage-associated molecular patterns (DAMPs) and inflammatory markers.


Eligibility

Min Age: 20 Years

Inclusion Criteria1

  • COPD patients willing to enter this study

Exclusion Criteria1

  • not COPD patients, no willing to enter this study

Interventions

COMBINATION_PRODUCTJing Si herbal tea (JSHT)

JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).

OTHERPlacebo

Placebo of JSHT


Locations(1)

Taipei Tzu Chi Hospital

New Taipei City, Xindan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06584786


Related Trials